Design, Conduct, and Analysis of Clinical Trials in Disease Due to Methicillin-Resistant Staphylococcus Aureus

We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. For further information on how we process and monitor your personal data, and information about your privacy and opt-out rights click here. By clicking the "Download button" you agree to the terms of our Privacy Policy.

Given the changing epidemiology of disease due to Staphylococcus aureus (SA), including the emergence of drug-resistant organisms such as methicillin-resistant SA, investigators may wish to evaluatethe effects of antimicrobials in disease due to SA as well as in disease due to other organisms in the same trial. Here JH Powers and TR Fleming discuss issues that investigators should address in trial design, conduct, and analysisto evaluate overall effects or effects within subgroups according tocausative organisms.